. Author manuscript; available in PMC: 2010 Aug 11.

Published in final edited form as: Ann Rheum Dis. 2010 Jan;69(1):97–101. doi: 10.1136/ard.2008.102137

Table 1.

Baseline characteristics of patients

	Patients with complete data for HAQ-DI	Patients with complete data for all scores
	N=370	N=281
Age (years)	58.37 ± 11.93	58.13 ± 11.87
Sex (female)	292 (78.92%)	225 (80.07%)
Rheumatoid factor positive	248 (66.85%)	174 (61.92%)
Disease duration (years)	9.84 ± 8.49	9.34 ± 8.25
Prior DMARD intake	325 (87.84%)	243 (86.48%)
Patient global assessment of disease activity	52.41 ± 19.08	52.82 ± 19.53
Physician global assessment of disease activity	51.58 ± 17.11	51.63 ± 17.12
Swollen joint count (/28)	9.78 ± 5.70	9.51 ± 5.76
Tender joint count (/28)	12.02 ± 6.58	11.98 ± 6.66
ESR (mm)	30.14 ± 22.25	30.46 ± 21.81
CRP level (mg/L)	23.43 ± 30.80	23.64 ± 31.03
DAS28	5.62 ±1.10	5.62 ± 1.11
HAQ-DI	1.40 ± 0.62	1.41± 0.61
	Range [0.00–2.87]	Range [0.12–2.75]

Data are presented as mean ± SD or n (%)

DAS: disease activity score; DMARD: disease-modifying anti-rheumatic drug; ESR: erythrocyte sedimentation rate; HAQ-DI: health assessment questionnaire disability index; CRP: C-reactive protein